Objective This systematic review seeks to survey existing literature concerning systemic lupus erythematosus (SLE)-related thrombosis risk mechanisms within six pro-coagulable categories: ...

Background Single-cell RNA-sequencing (scRNA-seq) has been recently applied in systemic lupus erythematosus (SLE) to define distinct cellular composition and transcriptional signatures, greatly ...

Objective BAFF and APRIL signal through TACI, BCMA, and/or BAFF-R, and play important roles in the activation, differentiation, and/or survival of B cells, particularly antibody-secreting cells, as ...

Methods Phase 2, multicenter, randomized, placebo-controlled, double-blind, parallel-group study enrolling adults with active, autoantibody-positive SLE with an inadequate response to one or more ...

Background Zetomipzomib is a first-in-class selective inhibitor of the immunoproteasome that offers anti-inflammatory properties without significant immunosuppression. 1 2 Methods The MISSION study is ...

Conclusion We are successfully using a “rare disease study” approach to conduct the first trial of a biologic therapy to prevent pregnancy complications in women with APS and LAC. Certolizumab appears ...

Background Discoid lupus erythematosus (DLE) is one of the LE-specific skin diseases on the scalp, and some cases induce scarring alopecia. In systemic LE (SLE), variable nail changes not specific to ...

Background Lupus nephritis (LN) is a common manifestation of systemic lupus erythematosus (SLE), with 10–30% progressing to end-stage renal disease (ESRD) and requiring dialysis. Kidney ...

Conclusions Chilblain lupus erythematosus is a rare and chronic disease mainly affecting women. Although it is not as severe as Systemic Lupus Erythematosus (SLE), it may be the sentinel sign of a ...

Background We employed urine proteomics to define the molecular signatures associated with the histological features quantified by the NIH activity and chronicity indices.Methods We employed urine ...

Background Often, patients present with clinical symptoms and immunologic abnormalities suggestive of systemic lupus erythematosus(SLE), while not meeting classification criteria yet. This is referred ...

Background Mutations, both activating and inactivating ones, continue to be identified in human diseases, including systemic lupus erythematosus (SLE). One emphasis is on mutations in transcription ...